1. Home
  2. GDV vs MLYS Comparison

GDV vs MLYS Comparison

Compare GDV & MLYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Gabelli Dividend & Income Trust of Beneficial Interest

GDV

Gabelli Dividend & Income Trust of Beneficial Interest

HOLD

Current Price

$29.22

Market Cap

2.5B

Sector

Finance

ML Signal

HOLD

Logo Mineralys Therapeutics Inc.

MLYS

Mineralys Therapeutics Inc.

HOLD

Current Price

$28.33

Market Cap

2.2B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GDV
MLYS
Founded
2003
2019
Country
United States
United States
Employees
N/A
N/A
Industry
Investment Managers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.5B
2.2B
IPO Year
N/A
2023

Fundamental Metrics

Financial Performance
Metric
GDV
MLYS
Price
$29.22
$28.33
Analyst Decision
Strong Buy
Analyst Count
0
6
Target Price
N/A
$48.67
AVG Volume (30 Days)
92.6K
1.2M
Earning Date
01-01-0001
05-11-2026
Dividend Yield
5.81%
N/A
EPS Growth
N/A
37.43
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$23.10
$12.59
52 Week High
$29.46
$47.65

Technical Indicators

Market Signals
Indicator
GDV
MLYS
Relative Strength Index (RSI) 69.84 52.12
Support Level $26.24 $26.85
Resistance Level $29.46 $31.19
Average True Range (ATR) 0.37 1.71
MACD 0.16 0.18
Stochastic Oscillator 92.54 40.56

Price Performance

Historical Comparison
GDV
MLYS

About GDV Gabelli Dividend & Income Trust of Beneficial Interest

Gabelli Dividend & Income Trust operates as a diversified closed-end management investment company. The fund's investment objective is to provide a high level of total return on its assets with an emphasis on dividends and income. To achieve its objective, the fund may invest its assets in dividend-paying securities or other income-producing securities. The fund invests in various sectors, including Financial Services, Food and Beverage, Health Care, Consumer Products, Electronics, and Computer Software & Services, and others.

About MLYS Mineralys Therapeutics Inc.

Mineralys Therapeutics Inc is a biopharmaceutical company focused on developing medicines to target diseases driven by dysregulated aldosterone. The Company's product candidate, lorundrostat, is a proprietary, orally administered, aldosterone synthase inhibitor that the Company is developing for the treatment of cardiorenal conditions affected by dysregulated aldosterone, including hypertension and related comorbidities, such as chronic kidney disease and obstructive sleep apnea. Its product candidate, lorundrostat, is a proprietary, orally administered, selective ASI that is designed to reduce aldosterone levels by inhibiting CYP11B2, the enzyme responsible for producing the hormone.

Share on Social Networks: